Top news of the week: 22.12.2021.
Companies And Industries
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19
Biopharmaceutical companies across the world are fighting an increasingly important battle against COVID-19: the struggle to treat the disease.
Sanofi buys US immuno-oncology biotech Amunix for $1 billion
Sanofi has bolstered its immuno-oncology pipeline with a $1 billion agreement to acquire Amunix Pharma of the US
Worst biopharma CEO of 2021? There are too many to choose just one
Worst biopharma CEO of 2021? Here's @adamfeuerstein's annual list.
It’s the cardiovascular version of Alzheimer’s — and, for a biotech with a promising drug, it could be a windfall
The prognosis for patients with ATTR-CM, which works like a cardiovascular version of Alzheimer’s disease, is changing as a result of new medications.
Valneva, Arcturus add to bombardment of booster boasting for COVID-19 shots
It’s the battle of the boosters. A day after Sanofi and GlaxoSmithKline said their COVID-19 shot works well as a booster for other shot regimens, Valneva and Arcturus Therapeutics are ...
Two Biotechs Uncloak to Deliver Affordable Biological Tools and Fight Dry Eye Disease
Nodexus and Aramis Biosciences will use their funds to expand their company’s pipeline and build their commercialization capabilities.
BioSpace Movers & Shakers, Dec. 17
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers.
23andMe, EQRx Lead IPO Rush in 2021
The year kicked off with a bang as multiple companies raced to a public listing.